Loading clinical trials...
Loading clinical trials...
An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
University of Arizona Arthritis Center /ID# 101359
Tucson, Arizona, United States
Dartmouth-Hitchcock Med Ctr /ID# 92596
Lebanon, New Hampshire, United States
Hackensack Univ Med Ctr /ID# 101417
Hackensack, New Jersey, United States
Start Date
December 20, 2013
Primary Completion Date
December 16, 2019
Completion Date
December 16, 2019
Last Updated
December 19, 2019
11
ACTUAL participants
ABT-199
DRUG
Lead Sponsor
AbbVie
Collaborators
NCT06667687
NCT05623982
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03314974